IP Library Patent Application 15776795
Patent Application
App. No. 15/776,795

HYDROGEL COATED MESH

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/776,795
Abstract

The invention provides biocompatible mesh compositions and preparations thereof. Also featured are methods of treatment using the biocompatible mesh compositions.

Claims (32)

1 . A biocompatible mesh composition comprising:

a mesh having a multi-layered molecular coating of hyaluronic acids, wherein the primary hydroxyl (—OH) groups of hyaluronic acids are cross-linked with the —OH containing groups on the mesh via a homobifunctional cross-linking agent, and the primary hydroxyl (—OH) groups of hyaluronic acids are also cross-linked to each other via the homobifunctional cross-linking agent.

2 . The biocompatible mesh composition of claim 1 , wherein the homobifunctional cross-linking agent is butanediol diglycidyl ether (BDDE), 1, 2, 7, 8-diepoxyoctane (DEO), glycerol diglycidyl ether, or divinyl sulfone (DVS).

3 . The biocompatible mesh composition of claim 1 , wherein the mesh is polystyrene, polyethylene, polypropylene, polyethylene terephthalate, polytefrafluoroethylene, polylactide, cellulose or silk.

4 . The biocompatible mesh composition of claim 1 , wherein the —OH containing groups on the mesh are represented by —RCH 2 OH, wherein R is C 1 -C 6 alkylene or R is absent.

5 . The biocompatible mesh composition of claim 4 , wherein the —OH containing groups are —CH 2 OH or —CH 2 CH 2 CH 2 OH.

6 . The biocompatible mesh composition of claim 1 , wherein the hyaluronic acid has a molecular weight in a range of from about 350,000 daltons to about 2,000,000 daltons.

7 . The biocompatible mesh composition of claim 1 , wherein the mesh is silk and the homobifunctional cross-linking agent is butanediol diglycidyl ether (BDDE).

8 . The biocompatible mesh composition of claim 1 , wherein the mesh is cellulose and the homobifunctional cross-linking agent is butanediol diglycidyl ether (BDDE).

9 . The biocompatible mesh composition of claim 1 , wherein the mesh is polypropylene and the homobifunctional cross-linking agent is butanediol diglycidyl ether (BDDE).

10 . The biocompatible mesh composition of claim 1 , wherein the molar ratio between the hyaluronic acid and the homobifunctional cross-linking agent is 20:1 to 1:1.

11 . The biocompatible mesh composition of claim 1 , wherein the molar ratio between the hyaluronic acid and the homobifunctional cross-linking agent is 15:1 to 1:1.

12 . The biocompatible mesh composition of claim 1 , wherein the mesh is in the form of a flexible sheet.

13 . A process of making a biocompatible mesh composition, the method comprising:

i) treating a mesh with plasma to form a mesh with —OH containing groups on its surface;

ii) contacting the mesh with —OH containing groups with a solution containing hyaluronic acids and a homobifunctional cross-linking agent to form a biocompatible mesh composition in which the mesh has a multi-layered molecular coating of hyaluronic acids such that the primary hydroxyl (—OH) groups of hyaluronic acids are cross-linked with the —OH containing groups on the mesh via the homobifunctional cross-linking agent, and the primary hydroxyl (—OH) groups of hyaluronic acids are also cross-linked to each other via the homobifunctional cross-linking agent.

14 . A process of making a biocompatible mesh composition, the method comprising:

contacting a mesh with —OH containing groups on its surface with a solution containing hyaluronic acid and a homobifunctional cross-linking agent, to form a biocompatible mesh composition in which the mesh has a multi-layered molecular coating of hyaluronic acids such that the primary hydroxyl (—OH) groups of hyaluronic acids are cross-linked with the —OH containing groups on the mesh via the homobifunctional cross-linking agent, and the primary hydroxyl (—OH) groups of hyaluronic acids are also cross-linked to each other via the homobifunctional cross-linking agent.

15 . The process of claim 13 , wherein the mesh is polystyrene, polyethylene, polypropylene, polyethylene terephthalate, polytefrafluoroethylene, polylactide, cellulose or silk.

16 . The process of claim 13 , wherein the process comprises a further step of allowing the biocompatible mesh composition to dry.

17 . The process of claim 13 , wherein the homobifunctional cross-linking agent is butanediol diglycidyl ether (BDDE), 1, 2, 7, 8-diepoxyoctane (DEO), glycerol diglycidyl ether, or divinyl sulfone (DVS).

18 . The process of claim 13 , wherein the concentration of the hyaluronic acid is between 5 mg/mL and 50 mg/mL.

19 . The process of claim 13 , wherein the concentration of the hyaluronic acid is between 25 mg/mL and 50 mg/mL.

20 . The process of claim 13 , wherein the hyaluronic acid has a molecular weight in a range of from about 350,000 daltons to about 2,000,000 daltons.

21 . The process of claim 13 , wherein the molar ratio between the hyaluronic acid and the homobifunctional cross-linking agent is 20:1 to 1:1.

22 . The process of claim 13 , wherein the molar ratio between the hyaluronic acid and the homobifunctional cross-linking agent is 15:1 to 1:1.

23 . The process of claim 13 , wherein the mesh is silk and the homobifunctional cross-linking agent is butanediol diglycidyl ether (BDDE).

24 . The process of claim 13 , wherein the mesh is cellulose and the homobifunctional cross-linking agent is butanediol diglycidyl ether (BDDE).

25 . The process of claim 13 , wherein the mesh is polypropylene and the homobifunctional cross-linking agent is butanediol diglycidyl ether (BDDE).

26 . The process of claim 13 , wherein the plasma treatment is in the presence of allyl alcohol.

27 . The process of claim 13 , wherein the mesh in the form of a flexible sheet.

28 . A biocompatible mesh composition formed by the process of claim 13 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2018
From: POMERLEAU, MING F.; OWENS, RICK T.
To: LIFECELL CORPORATION
Reel/Frame 046657/0178 →